Inventiva (IVA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Inventiva (IVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8260
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Inventiva is a clinical stage biopharmaceutical company that discovers and develops therapies for fibrosis, oncology and orphan diseases. The company develops pipeline products for nonalcoholic steatohepatitis, systemic sclerosis, mucopolysaccharidosis, moderate to severe psoriasis, malignant mesothelioma, multiple myeloma, immuno-oncology and idiopathic pulmonary fibrosis indications. It develops a novel internal cancer and fibrosis discovery pipeline with nuclear receptor platform, epigenetic platform, fibriva, DMPK, ivalib and screening platforms, pharmacology, and target validation. The company advances small-molecule therapies for auto-immune disorders and operates the Epicure project. It conducts its drug discovery research in partnership with various medical organizations. Inventiva is headquartered in Daix, France.

Inventiva (IVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inventiva, Medical Devices Deals, 2012 to YTD 2018 10
Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inventiva, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Inventiva Pharma Raises USD43.8 Million in Private Placement of Shares 12
Partnerships 14
Curie-Cancer Partners with Inventiva 14
NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 15
Inventiva Extends Agreement with AbbVie 16
Licensing Agreements 17
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 17
Equity Offering 18
Inventiva Plans to Raise USD37 Million in Private Placement of Shares 18
Inventiva Raises USD53 Million in IPO 20
Inventiva – Key Competitors 21
Inventiva – Key Employees 22
Inventiva – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Jul 19, 2018: Inventiva reports first-half 2018 financial results and provides corporate update 24
May 15, 2018: Inventiva: First-quarter 2018 financial update 26
Mar 07, 2018: Inventiva: 2017 Full Year Results 28
Feb 12, 2018: Inventiva Reports Full-Year 2017 Financial Results 30
Nov 07, 2017: Inventiva: Third-Quarter 2017 Financial Information 32
Sep 26, 2017: Inventiva: First-Half 2017 Results 33
Jul 05, 2017: Inventiva Announces First-half 2017 Financial and Corporate Update 37
Apr 25, 2017: Inventiva: First-Quarter 2017 Financial Update 39
Corporate Communications 40
Oct 17, 2018: Inventiva announces two appointments to its management team ahead of future key development milestones 40
May 28, 2018: Dr Lucy Lu is appointed to the Inventiva Board of Directors 41
May 30, 2017: Dr Nanna Luneborg, Principal of Novo Ventures, Joins Inventiva’s Board 42
Product News 43
07/27/2017: Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA 43
Clinical Trials 44
Sep 18, 2017: Inventivas IVA337 Given Generic Name “Lanifibranor”by the World Health Organization (WHO) 44
Jun 20, 2017: Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models 45
May 15, 2017: Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337 46
Apr 20, 2017: Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress 2017 47
Apr 10, 2017: Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis 48
Jan 03, 2017: Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis 49
Other Significant Developments 50
Sep 24, 2018: Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Inventiva, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inventiva, Deals By Therapy Area, 2012 to YTD 2018 9
Inventiva, Medical Devices Deals, 2012 to YTD 2018 10
Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inventiva Pharma Raises USD43.8 Million in Private Placement of Shares 12
Curie-Cancer Partners with Inventiva 14
NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 15
Inventiva Extends Agreement with AbbVie 16
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 17
Inventiva Plans to Raise USD37 Million in Private Placement of Shares 18
Inventiva Raises USD53 Million in IPO 20
Inventiva, Key Competitors 21
Inventiva, Key Employees 22

List of Figures
Inventiva, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inventiva, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inventiva, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Inventiva (IVA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Globeleq Africa Ltd:企業の戦略的SWOT分析
    Globeleq Africa Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Reliance Infrastructure Ltd.:企業の戦略・SWOT・財務分析
    Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report Summary Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SANUWAVE Health Inc (SNWV):医療機器:M&Aディール及び事業提携情報
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company offers products such as dermapace, which is used in the treatment of chronic and acute conditions o …
  • Difference Capital Financial Inc.:企業のM&A・事業提携・投資動向
    Difference Capital Financial Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Difference Capital Financial Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Axis Bank Limited:企業の戦略・SWOT・財務情報
    Axis Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Axis Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Thirau Inc.:企業の戦略的SWOT分析
    Thirau Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GAIN Capital Holdings, Inc.:企業のM&A・事業提携・投資動向
    GAIN Capital Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GAIN Capital Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Sapura Energy Bhd (SENERGY):企業の財務・戦略的SWOT分析
    Sapura Energy Bhd (SENERGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Pinsent Masons LLP:企業の戦略的SWOT分析
    Pinsent Masons LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Vitae Pharmaceuticals Inc (VTAE)-製薬・医療分野:企業M&A・提携分析
    Summary Vitae Pharmaceuticals Inc (Vitae Pharmaceuticals) is a biopharmaceutical company that offers pharmaceutical products. The company discovers and develops and small molecule drugs for diseases with significant unmet medical needs. Its products pipeline includes VTP-34072, BI 1147560, VTP-43742 …
  • Martin Midstream Partners L.P.:企業の戦略・SWOT・財務情報
    Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Caverion Corp:企業の戦略・SWOT・財務情報
    Caverion Corp - Strategy, SWOT and Corporate Finance Report Summary Caverion Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Corus Entertainment Inc. (CJR.B):企業の財務・戦略的SWOT分析
    Corus Entertainment Inc. (CJR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • China North Industries Corporation:企業の戦略・SWOT・財務情報
    China North Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary China North Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Capture Vascular Inc:医療機器:M&Aディール及び事業提携情報
    Summary Capture Vascular Inc (Capture Vascular) is a medical device development company that develops and commercializes mechanical thrombectomy systems. The company offers MegaVac, a mechanical thrombectomy system that removes clots in arteries and provides vessel occlusion, embolic prevention and …
  • Electricity Generating Public Co Ltd (EGCO)-エネルギー分野:企業M&A・提携分析
    Summary Electricity Generating Public Co Ltd (EGCO), a subsidiary of Electricity Generating Authority of Thailand (EGAT), is an energy utility. It produces electricity from natural gas, coal, biomass, waste, hydro, solar, wind, and geothermal sources. Through interests in independent power producer …
  • Zenosense Inc (ZENO):医療機器:M&Aディール及び事業提携情報
    Summary Zenosense Inc (Zenosense) is a medical device company that develops transformational medical diagnostic technologies. The company develops MIDS Cardiac, a hand held cardiac diagnostic device that applies patent-protected magnetic nanoparticle detection technology used for the rapid testing o …
  • Old Mutual Plc:戦略・SWOT・企業財務分析
    Old Mutual Plc - Strategy, SWOT and Corporate Finance Report Summary Old Mutual Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sibanye Gold Ltd:企業の戦略・SWOT・財務情報
    Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Euroclear Plc
    Euroclear Plc - Strategy, SWOT and Corporate Finance Report Summary Euroclear Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆